Successful guselkumab treatment in a psoriatic patient affected with Cornelia de Lange syndrome, and prosecution during the COVID-19 pandemic.
COVID-19
Cornelia de Lange syndrome
guselkumab
intellectual disability
psoriasis
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
13
04
2020
accepted:
14
04
2020
pubmed:
20
4
2020
medline:
1
12
2020
entrez:
20
4
2020
Statut:
ppublish
Résumé
Psychomotor delay and intellectual disability are potential limitations in psoriasis management, due to low compliance, and strict dependence from caregivers intervention. We report our successful experience with a 58-year-old woman, who was genetically affected by Cornelia De Lange syndrome, which causes intellectual disability and psychomotor disorders. The patient had been already treated with topical and traditional therapies, without any clinical benefits. Eventually, she adhered to guselkumab treatment. The compliance was excellent, significant improvements were observed after only 3 months of treatment, without adverse effects. During follow-up, the COVID-19 pandemic address concern on the possible increased risk of infection due to immunosuppression. In agreement with current Italian recommendations, risk and benefits profile was discussed with the patient's legal tutor and the decision to continue the treatment was taken. Psoriasis complete clarification was maintained during the most difficult period of the Italian outbreak, allowing the patient to remain safely at home.
Substances chimiques
Antibodies, Monoclonal, Humanized
0
guselkumab
089658A12D
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13433Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Kouris A, Platsidaki E, Kouskoukis C, Christodoulou C. Psychological parameters of psoriasis. Psychiatriki. 2017;28:54-59.
Augustin M, Holland B, Dartsch D, Langenbruch A, Radtke MA. Adherence in the treatment of psoriasis: a systematic review. Dermatology. 2011;222:363-374.
Zaghloul SS, Goodfield MJ. Objective assessment of compliance with psoriasis treatment. Arch Dermatol. 2004;140:408-414.
Boyle MI, Jespersgaard C, Brøndum-Nielsen K, Bisgaard A-M, Tümer Z. Cornelia de Lange syndrome. Clin Genet. 2015;88:1-12.
Pié J, Puisac B, Hernández-Marcos M, et al. Special cases in Cornelia de Lange syndrome: the Spanish experience. Am J Med Genet C Semin Med Genet. 2016;172:198-205.
Nogueira M, Torres T. Guselkumab for the treatment of psoriasis-evidence to date. Drugs Context. 2019;8:212594.
Gazzetta Ufficiale, Serie Generale n.62 del 09-03-2020, https://www.gazzettaufficiale.it/eli/gu/2020/03/09/62/sg/pdf.
Price KN, Frew JW, Hsiao JL, Shi VY. COVID-19 and immunomodulator/immunosuppressant use in dermatology. J Am Acad Dermatol. 2020;82:e173-e175.
Infezione da Coronavirus-Raccomandazioni SIDeMaST (Società Italiana di Dermatologia e Malattie Sessualmente Trasmesse), https://www.sidemast.org/blog/coronavirus/; published on February 25, 2020.